Cargando…
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer
Genetic alterations in RET lead to activation of ERK and AKT signaling and are associated with hereditary and sporadic thyroid cancer and lung cancer. Highly selective RET inhibitors have recently entered clinical use after demonstrating efficacy in treating patients with diverse tumor types harbori...
Autores principales: | Raman, Renuka, Villefranc, Jacques A., Ullmann, Timothy M., Thiesmeyer, Jessica, Anelli, Viviana, Yao, Jun, Hurley, James R., Pauli, Chantal, Bareja, Rohan, Wha Eng, Kenneth, Dorsaint, Princesca, Wilkes, David C., Beg, Shaham, Kudman, Sarah, Shaw, Reid, Churchill, Michael, Ahmed, Adnan, Keefer, Laurel, Misner, Ian, Nichol, Donna, Gumpeni, Naveen, Scognamiglio, Theresa, Rubin, Mark A., Grandori, Carla, Solomon, James Patrick, Song, Wei, Mosquera, Juan Miguel, Dephoure, Noah, Sboner, Andrea, Elemento, Olivier, Houvras, Yariv |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082625/ https://www.ncbi.nlm.nih.gov/pubmed/35510953 http://dx.doi.org/10.1084/jem.20210390 |
Ejemplares similares
-
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells
por: Chang, Hyun, et al.
Publicado: (2017) -
Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018) -
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020) -
Oncogenic BRAF disrupts thyroid morphogenesis and function via twist expression
por: Anelli, Viviana, et al.
Publicado: (2017) -
Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)